Spectrum Pharmaceuticals Inc said a mid-stage trial of its experimental blood cancer drug met the main goal of shrinking tumors.
The drug, belinostat, was tested in patients with relapsed/refractory peripheral T-Cell (PTCL) lymphoma, who have failed at least one therapy.
The biotechnology company said it expects to file a marketing application with U.S. health regulators by mid-2013, and expects a review date in 2014.
Belinostat was granted orphan-drug status and fast-track status by the U.S. Food and Drug Administration for PTCL.
Spectrum's shares, which have fallen about 22 percent in the last year, closed at $11.30 on the Nasdaq on Thursday.
Spectrum Pharma's blood cancer drug meets goal in mid-stage trial
This article
Spectrum Pharma's blood cancer drug meets goal in mid-stage trial
can be opened in url
https://newserfortune.blogspot.com/2012/12/spectrum-pharmas-blood-cancer-drug_26.html
Spectrum Pharma's blood cancer drug meets goal in mid-stage trial
